How psychedelics could stage a comeback on Wall Street

Pharmaceutical and biotech companies in the psychedelics space are advancing toward a potential FDA approval. TD Cowen’s Ritu Baral discusses the industry’s challenges and the potential impact on patients’ mental health if these hurdles are overcome.